An innovative vaccine developed by IISc has been approved by the Food and Drug Administration (FDA) to fight meningococcal disease.

The vaccine, which was developed by scientists from the National Institute of Biotechnology and Biological Sciences (NIBBS), is currently being tested on pigs.

The vaccine was approved by FDA on Wednesday and will be licensed to the national veterinary hospital, NIAID said.

The NIBBS researchers are conducting a study in India to understand the effects of a single dose of the vaccine on meningovirus (MV) infection rates.

This study will also investigate the efficacy and safety of the drug and vaccines in the field.

“A new vaccine is a powerful weapon in the battle against meningocaris, but we need more time before we can make it available for the general population,” said NIAIDs director, Dr. Kavita Ramakrishnan.

Meningococcal infections are on the rise in the US, particularly in the Northeast, the Midwest and the South, according to the Centers for Disease Control and Prevention.

The disease is caused by a different species of bacteria called meningitidis.

According to the National Institutes of Health, M. meningivirus infections in the United States reached 1.2 million in the first three months of 2019.

Mingoviruses can be transmitted through the air or through contaminated surfaces such as clothing, shoes and toys.

The CDC has not yet found a vaccine that can completely prevent or cure M. mannose infection, but researchers are exploring new ways to tackle this outbreak.

In addition to being used to treat meningosarcoma (MS) in adults, the vaccine is being tested for efficacy in children.

“We’re taking our time and making sure we understand how this vaccine works, and that we are getting it right,” said Dr. J. David Lasker, head of the NIAIDS vaccine program.

“We’re not looking for a quick fix.

We’re not doing an overnight fix.

Our priority is to make sure that we get the right vaccine and do the right things.”